## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 1.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($332.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. What Do Analysts Think About Elevance Health (ELV)?**
- Source: Finviz | 20251230T070804 | Neutral | Relevance: 100%
- Deutsche Bank analyst George Hill downgraded Elevance Health (ELV) to Hold and reduced its price target to $320 from $332 on December 19, whereas BofA increased its price target to $385 from $370 on December 16, reaffirming a Neutral rating. Elevance Health also announced the appointment of Amy Schulman as an independent director, effective January 12, 2026, and expanded access to its Virtual Assistant digital experience. The company operates through several segments including Health Benefits, CarelonRx, and Carelon Services.

**2. UNH vs. ELV: Which Managed Care Stock Has the Edge Today?**
- Source: The Globe and Mail | 20251230T182848 | Somewhat-Bullish | Relevance: 100%
- This article compares UnitedHealth Group (UNH) and Elevance Health (ELV), two major players in the U.S. managed healthcare sector. While UNH, the largest insurer, benefits from its diversified Optum segment, it faces challenges from rising medical costs and regulatory scrutiny. ELV, despite also facing cost pressures, presents a stronger near-term risk-reward profile due to strategic exits from underperforming markets, the growth of its Carelon platform, and a more appealing valuation.

**3. Can Elevance (ELV) Hike Prices to Accommodate Rising Costs?**
- Source: Insider Monkey | 20251230T070100 | Bullish | Relevance: 100%
- Artisan Value Fund recently invested in Elevance Health, Inc. (NYSE:ELV), highlighting its potential for recovery as pricing adjusts to increasing costs and its stock price multiple normalizes. This move comes as the fund swapped Cigna for Elevance due to differences in business mix, particularly regarding PBM reform risks. Elevance, one of the largest health insurers, is seen as undervalued with depressed earnings expected to recover.

**4. Marathon Asset Management Ltd Acquires 3,859 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251229T114420 | Somewhat-Bullish | Relevance: 100%
- Marathon Asset Management Ltd increased its stake in Elevance Health (NYSE:ELV) by 1.5% in the third quarter, purchasing an additional 3,859 shares to own a total of 267,395 shares valued at approximately $86.4 million. This makes Elevance Health its seventh-largest holding, representing 0.12% of the company. The company recently reported strong Q3 earnings, beating analyst expectations with $6.03 EPS and $50.09 billion in revenue, and analysts currently rate the stock a "Moderate Buy" with an average price target of $396.21.

**5. Ethic Inc. Reduces Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251229T101334 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 17.0% in Q3, selling 6,761 shares and holding 33,008 shares valued at approximately $10.67 million. Despite this reduction, several other institutional investors increased their positions in ELV during recent quarters. Elevance Health reported strong Q3 earnings, beating analyst estimates with an EPS of $6.03 and revenue of $50.09 billion, and it maintains a "Moderate Buy" consensus rating from analysts with an average price target of $396.21.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.5B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 13.0 |
| Current P/E | 11.6 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.0% to 0.4% (+3.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 57. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.36% (CS: 70) | Neutral |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | -0.21 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $348.87
- **Stop Loss:** $332.77 (4.6% risk)
- **Target:** $364.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $28,258.47
- **Portfolio %:** 28.26%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*